首页 | 本学科首页   官方微博 | 高级检索  
检索        

伊伐布雷定在心血管疾病中的研究新进展
引用本文:于怡卉,李明慧,许周涛,胡作英.伊伐布雷定在心血管疾病中的研究新进展[J].中华临床医师杂志(电子版),2014(14):139-142.
作者姓名:于怡卉  李明慧  许周涛  胡作英
作者单位:南京医科大学附属南京第一医院心内科,210000
摘    要:伊伐布雷定为首个特异性心脏起搏电流抑制剂,具有特异性减慢心率的作用,且在减慢心率的同时不影响心脏收缩功能。目前很多临床研究证实,伊伐布雷定对冠心病、快速型窦性心律失常、心力衰竭、心肌梗死等有明确的疗效。现对伊伐布雷定药理机制及其在临床应用中的研究新进展进行综述。

关 键 词:冠心病  心律失常  心力衰竭  心肌梗死  伊伐布雷定  I(f)抑制剂

The advance on the research of Ivabradine in cardiovascular disease
Yu Yihui,Li Minghui,Xu Zhoutao,Hu Zuoying.The advance on the research of Ivabradine in cardiovascular disease[J].Chinese Journal of Clinicians(Electronic Version),2014(14):139-142.
Authors:Yu Yihui  Li Minghui  Xu Zhoutao  Hu Zuoying
Institution:( Department of Cardiology, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210000, China)
Abstract:Ivabradine is the first cardiac pacing current (If current) inhibitor that specifically reduces heart rate without affecting myocardial contractility or ventricular systolic function. At present, many clinical studies have shown that Ivabradine has a definite curative effect on patients with coronary heart disease, fast sinus rhythm disorders and heart failure. This review summarized the application and advance of Ivabradine in clinical cardiovascular diseases and its pharmacological mechanisms.
Keywords:Coronary heart disease  Arrhythmia  Heart failure  Myocardial infarction  Ivabradine  I(f) inhibitor
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号